Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Evaluation of Post-Procedure Administration of Celecoxib Following Shoulder Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-10-09
- Last Posted Date
- 2018-04-27
- Lead Sponsor
- St. Louis Joint Replacement Institute
- Target Recruit Count
- 150
- Registration Number
- NCT03305068
- Locations
- 🇺🇸
SSM DePaul, Bridgeton, Missouri, United States
Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Armed Forces Capital Hospital, Republic of Korea
- Target Recruit Count
- 12
- Registration Number
- NCT03190603
- Locations
- 🇰🇷
Armed Forces Capital Hospital, Seongnam-si, Korea, Republic of
Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- University of Wisconsin, Madison
- Registration Number
- NCT03185871
Celebrex and Metformin for Postoperative Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Guangxi Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT03184493
- Locations
- 🇨🇳
Affiliated Tumor Hospital of Guangxi Medical University, Nanjing, Guangxi, China
Pain Management in Head and Neck Surgery Patients
- Conditions
- Interventions
- First Posted Date
- 2017-04-20
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT03121963
PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
- Conditions
- Interventions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 134
- Registration Number
- NCT03084536
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
99Tc-MDP Treatment for Knee Osteoarthritis
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 40
- Registration Number
- NCT02993029
- Locations
- 🇨🇳
Department of Nuclear Medicine, Tenth People's Hospital of Tongji University, Shanghai, Shanghai, China
Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 23
- Registration Number
- NCT02987920
Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 116
- Registration Number
- NCT02961998
Celecoxib After Tonsillectomy
- Conditions
- Interventions
- First Posted Date
- 2016-10-14
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 172
- Registration Number
- NCT02934191
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.